{
    "nctId": "NCT01239745",
    "briefTitle": "Aromasin\u00ae As Adjuvant Treatment In Postmenopausal Women With Invasive, Estrogen Receptor Positive Early Breast Cancer",
    "officialTitle": "A Non-Interventional Study With Aromasin\u00ae As Adjuvant Treatment In Postmenopausal Women With Invasive, Estrogen Receptor Positive Early Breast Cancer Who Are Disease-Free After 2-3 Years Of Initial Adjuvant Tamoxifen Therapy",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Neoplasms",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 46,
    "primaryOutcomeMeasure": "Number of Participants With Adverse Events (AEs)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Postmenopausal females, defined as one from the next :\n\n  1. Natural menopause \u22651 year,\n  2. Surgical ovariectomy,\n  3. Chemotherapy-induced amenorrhoea \u2265 2 years.\n* Patients who have had surgical treatment for histologically confirmed breast cancer that was non-metastatic at the time of the initial diagnosis.\n* Patients who are disease-free after 2 to 3 years of adjuvant tamoxifen treatment.\n* Patients whose tumour was estrogen receptor positive (ER+).\n* Evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study.\n\nExclusion Criteria:\n\n* Patients for whom Aromasin\u00ae treatment is contraindicated (see SmPC).\n* Metastatic breast cancer or a contra lateral tumour.\n* Other concomitant adjuvant endocrine therapy.\n* Other concomitant antineoplastic treatment.\n* Participation in a clinical trial with an investigational drug during the 30 days prior to enrolment in the study.",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}